Edgar Dippel

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Lisa Zimmer, Elisabeth Livingstone, Jessica C. Hassel et al. · The Lancet · 2020 · 242 citations

Medicine, Immunology, Oncology +14

Differential expression of a gene signature for scavenger/lectin receptors by endothelial cells and macrophages in human lymph node sinuses, the primary sites of regional metastasis

J‐H Martens, Julia Kzhyshkowska, M Falkowski‐Hansen et al. · The Journal of Pathology · 2006 · 122 citations

Medicine, Molecular Biology, Oncology +12

Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG)

Chalid Assaf, Sylke Gellrich, Matthias Steinhoff et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2007 · 116 citations

Medicine, Dermatology, Oncology +11

Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3

Nina Booken, Alexei Gratchev, Jochen Utikal et al. · Leukemia · 2007 · 108 citations

Medicine, Dermatology, Oncology +15

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

Elisabeth Livingstone, Lisa Zimmer, Jessica C. Hassel et al. · The Lancet · 2022 · 108 citations

Medicine, Immunology, Oncology +16